Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
AbbVie Inc. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The analysis of investment activity ratios reveals a period of stability in asset utilization contrasted by an exponential increase in equity turnover. While the efficiency of fixed and total assets remains relatively consistent, the relationship between revenue and shareholder equity undergoes a dramatic shift starting in 2024.
- Net Fixed Asset Turnover
- The net fixed asset turnover ratio exhibits minimal volatility, fluctuating within a narrow range between 10.80 and 11.82. A peak was observed in September 2022 at 11.82, followed by a gradual decline to a low of 10.80 in September 2024. The ratio subsequently stabilized and showed a slight recovery, ending at 11.11 by June 2026. This indicates a consistent ability to generate revenue from fixed investments over the analyzed period.
- Total Asset Turnover
- Total asset turnover demonstrates a stable trajectory with a gradual positive trend in the later stages. From March 2022 to December 2023, the ratio remained largely stagnant between 0.37 and 0.42. However, starting in December 2023, a consistent upward trend emerged, with the ratio rising from 0.40 to 0.48 by June 2026. This progression suggests a marginal but steady improvement in the overall efficiency of the company's total asset base in generating sales.
- Equity Turnover
- Equity turnover displays the most significant variance, characterized by a sharp and accelerating upward trend. The ratio began at 3.48 in March 2022 and grew moderately to 5.24 by December 2023. A period of rapid acceleration commenced in March 2024, with the ratio climbing from 6.79 to 16.94 by December 2024, before reaching a peak of 40.40 in March 2025. Such an exponential increase typically suggests a substantial reduction in shareholder equity relative to revenue, potentially indicating aggressive capital restructuring or significant returns to shareholders.
Net Fixed Asset Turnover
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Net revenues | ||||||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||
| Net fixed asset turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Net fixed asset turnover
= (Net revenuesQ2 2026
+ Net revenuesQ1 2026
+ Net revenuesQ4 2025
+ Net revenuesQ3 2025)
÷ Property and equipment, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The net fixed asset turnover ratio exhibits a period of initial volatility followed by a trend of gradual contraction and subsequent stabilization. While net revenues show a long-term upward trajectory, characterized by recurring quarterly fluctuations, the investment in property and equipment increased more steadily in the latter half of the analyzed period, influencing the overall asset efficiency.
- Revenue Growth and Seasonality
- Net revenues increased from 13,538 million US dollars in March 2022 to 16,990 million US dollars by June 2026. A recurring seasonal pattern is evident, with revenue contractions typically occurring in the first quarter of each year, followed by consistent growth throughout the remaining three quarters.
- Fixed Asset Investment Trends
- Property and equipment, net, remained relatively stagnant between March 2022 and December 2023, fluctuating within a narrow range between 4,893 million and 5,075 million US dollars. A sustained upward trend commenced in 2024, with the net value of fixed assets rising to 5,796 million US dollars by June 2026, indicating an expansion of the physical asset base.
- Net Fixed Asset Turnover Performance
- The turnover ratio peaked at 11.82 in September 2022 before entering a period of decline, reaching a minimum of 10.80 in September 2024. This downward movement indicates that the growth in fixed assets initially outpaced the corresponding increase in revenue. Since late 2024, the ratio has stabilized and shown a marginal recovery, ending at 11.11 in June 2026, suggesting that revenue generation is beginning to synchronize with the expanded capacity of the fixed asset investments.
Total Asset Turnover
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Net revenues | ||||||||||||||||||||||||
| Total assets | ||||||||||||||||||||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||
| Total asset turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Total Asset Turnover, Competitors2 | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Total asset turnover
= (Net revenuesQ2 2026
+ Net revenuesQ1 2026
+ Net revenuesQ4 2025
+ Net revenuesQ3 2025)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial data indicates a general improvement in asset utilization efficiency over the analyzed period from March 2022 to June 2026. While the asset turnover ratio experienced a period of stagnation and a brief decline in early 2024, a consistent upward trend emerged thereafter, culminating in the highest efficiency level of 0.48 by the end of the period.
- Net Revenue Trends
- Net revenues exhibit a overall growth trajectory, rising from 13,538 million USD in March 2022 to 16,990 million USD by June 2026. A recurring seasonal pattern is observable, characterized by dips in the first quarter of each year followed by steady growth through the remainder of the fiscal cycle. This growth in the top line served as the primary driver for the eventual increase in the asset turnover ratio.
- Total Asset Management
- The asset base remained relatively stable, fluctuating primarily between 133,000 million USD and 149,000 million USD. A notable spike in total assets occurred in March 2024, reaching 148,874 million USD. Following this peak, the asset base trended downward and stabilized around 135,000 million USD toward 2026, contributing to improved efficiency as the company generated higher revenues from a leaner asset base.
- Total Asset Turnover Analysis
- The asset turnover ratio remained largely flat between 0.40 and 0.42 from March 2022 through December 2023. A significant decline to 0.37 was recorded in March 2024, coinciding with the period of peak total assets and seasonal revenue lows. However, from June 2024 onward, the ratio entered a period of sustained expansion, increasing from 0.39 to 0.48. This progression suggests an enhanced ability to generate sales per unit of investment in assets, reflecting improved operational efficiency and better alignment between the company's resource base and its revenue-generating capacity.
Equity Turnover
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Net revenues | ||||||||||||||||||||||||
| Stockholders’ equity (deficit) | ||||||||||||||||||||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||
| Equity turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Equity Turnover, Competitors2 | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Equity turnover
= (Net revenuesQ2 2026
+ Net revenuesQ1 2026
+ Net revenuesQ4 2025
+ Net revenuesQ3 2025)
÷ Stockholders’ equity (deficit)
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial results demonstrate a stark divergence between revenue growth and the stability of the equity base, resulting in a mathematical acceleration of the equity turnover ratio over the analyzed period.
- Revenue Trajectory
- Net revenues show a consistent long-term upward trend, increasing from 13.54 billion US dollars in March 2022 to 16.99 billion US dollars by June 2026. Although a recurring seasonal pattern is evident—with dips typically occurring in the first quarter of each year—the overall growth remains steady.
- Equity Position Analysis
- A significant and continuous decline in stockholders' equity is observed. The equity balance fell from 16.28 billion US dollars in March 2022 to a deficit of 5.94 billion US dollars by June 2026. The capital structure transitioned into a negative equity position between March 2025 and June 2025, indicating that liabilities have exceeded assets.
- Equity Turnover Interpretation
- The equity turnover ratio exhibited a dramatic increase, moving from 3.48 in March 2022 to 40.40 by March 2025. This surge is primarily driven by the collapse of the equity denominator rather than proportional increases in revenue. As the equity base diminished toward zero, the ratio became hyper-sensitive, leading to an exponential rise that reflects capital depletion or aggressive capital return strategies rather than improved operational asset efficiency.